BR112020005078A2 - proteínas de ligação a nkg2d, cd16, e molécula 1 semelhante a lecitina de tipo c (cll-1) - Google Patents
proteínas de ligação a nkg2d, cd16, e molécula 1 semelhante a lecitina de tipo c (cll-1) Download PDFInfo
- Publication number
- BR112020005078A2 BR112020005078A2 BR112020005078-4A BR112020005078A BR112020005078A2 BR 112020005078 A2 BR112020005078 A2 BR 112020005078A2 BR 112020005078 A BR112020005078 A BR 112020005078A BR 112020005078 A2 BR112020005078 A2 BR 112020005078A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- variable domain
- binding site
- chain variable
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US62/558,510 | 2017-09-14 | ||
| PCT/US2018/050916 WO2019055677A1 (en) | 2017-09-14 | 2018-09-13 | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020005078A2 true BR112020005078A2 (pt) | 2020-10-13 |
Family
ID=65723086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020005078-4A BR112020005078A2 (pt) | 2017-09-14 | 2018-09-13 | proteínas de ligação a nkg2d, cd16, e molécula 1 semelhante a lecitina de tipo c (cll-1) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200277384A1 (https=) |
| EP (1) | EP3681532A4 (https=) |
| JP (2) | JP2020534269A (https=) |
| KR (1) | KR20200051789A (https=) |
| CN (1) | CN111432832A (https=) |
| AU (1) | AU2018331412A1 (https=) |
| BR (1) | BR112020005078A2 (https=) |
| CA (1) | CA3075857A1 (https=) |
| EA (1) | EA202090718A1 (https=) |
| IL (1) | IL273206A (https=) |
| MA (1) | MA50255A (https=) |
| MX (1) | MX2020002880A (https=) |
| SG (1) | SG11202002298PA (https=) |
| WO (1) | WO2019055677A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EP3765516A2 (en) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| CN112912400B (zh) | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| BR112021020999A2 (pt) * | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos de ligação à clec12a e usos dos mesmos |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| PE20221316A1 (es) * | 2019-10-15 | 2022-09-07 | Dragonfly Therapeutics Inc | Proteinas que se unen a nkg2d, cd16 y flt3 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| JP7512394B2 (ja) * | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| JP2023524997A (ja) * | 2020-05-06 | 2023-06-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CA3216770A1 (en) | 2021-04-26 | 2022-11-03 | Tomoki Yoshihara | Anti-clec12a antibodies and uses thereof |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| CN115850476B (zh) * | 2022-08-09 | 2023-09-05 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| AU2008337517B2 (en) * | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| US10865233B2 (en) * | 2008-12-18 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | NKG2D-fc for immunotherapy |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| HUE042040T2 (hu) * | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| MA55746A (fr) * | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
| CA3177692A1 (en) * | 2017-02-27 | 2018-08-30 | Dragonfly Therapeutics, Inc. | Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, or claudin-18.2 |
-
2018
- 2018-09-13 EA EA202090718A patent/EA202090718A1/ru unknown
- 2018-09-13 CA CA3075857A patent/CA3075857A1/en active Pending
- 2018-09-13 BR BR112020005078-4A patent/BR112020005078A2/pt not_active Application Discontinuation
- 2018-09-13 CN CN201880072887.1A patent/CN111432832A/zh active Pending
- 2018-09-13 WO PCT/US2018/050916 patent/WO2019055677A1/en not_active Ceased
- 2018-09-13 MA MA050255A patent/MA50255A/fr unknown
- 2018-09-13 JP JP2020514936A patent/JP2020534269A/ja active Pending
- 2018-09-13 MX MX2020002880A patent/MX2020002880A/es unknown
- 2018-09-13 US US16/645,613 patent/US20200277384A1/en not_active Abandoned
- 2018-09-13 AU AU2018331412A patent/AU2018331412A1/en not_active Abandoned
- 2018-09-13 SG SG11202002298PA patent/SG11202002298PA/en unknown
- 2018-09-13 KR KR1020207010605A patent/KR20200051789A/ko not_active Ceased
- 2018-09-13 EP EP18856132.8A patent/EP3681532A4/en active Pending
-
2020
- 2020-03-10 IL IL273206A patent/IL273206A/en unknown
-
2024
- 2024-04-03 JP JP2024060206A patent/JP2024099539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018331412A1 (en) | 2020-03-26 |
| SG11202002298PA (en) | 2020-04-29 |
| EP3681532A1 (en) | 2020-07-22 |
| EP3681532A4 (en) | 2021-09-01 |
| CN111432832A (zh) | 2020-07-17 |
| MA50255A (fr) | 2021-05-26 |
| JP2024099539A (ja) | 2024-07-25 |
| EA202090718A1 (ru) | 2020-07-01 |
| WO2019055677A1 (en) | 2019-03-21 |
| MX2020002880A (es) | 2020-10-01 |
| IL273206A (en) | 2020-04-30 |
| JP2020534269A (ja) | 2020-11-26 |
| KR20200051789A (ko) | 2020-05-13 |
| CA3075857A1 (en) | 2019-03-21 |
| US20200277384A1 (en) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020005078A2 (pt) | proteínas de ligação a nkg2d, cd16, e molécula 1 semelhante a lecitina de tipo c (cll-1) | |
| ES2986967T3 (es) | Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D | |
| ES2954851T3 (es) | Proteínas de unión multiespecífica que se unen a HER2, NKG2D y CD16, y métodos de uso | |
| AU2018220734B2 (en) | Proteins binding CD33, NKG2D and CD16 | |
| AU2018329937B2 (en) | Proteins binding nkg2d, cd16 and nectin4 | |
| ES2955074T3 (es) | Proteínas que se unen a HER2, NKG2D Y CD16 | |
| BR112020003050A2 (pt) | proteínas de ligação a nkg2d, cd16, e egfr, hla-e, ccr4 ou pd-l1 | |
| US20200157174A1 (en) | Proteins binding nkg2d, cd16 and ror1 or ror2 | |
| BR112021002278A2 (pt) | proteínas que ligam nkg2d, cd16 e um antígeno associado a tumor | |
| BR112019016424A2 (pt) | proteínas de ligação a bcma, nkg2d e cd16 | |
| BR112019017758A2 (pt) | proteínas multispecíficas de ligação ao alvo caixa, ano1, mesotelina, trop2, cea ou claudin-18.2 | |
| BR112019024620A2 (pt) | Ligante de proteína nkg2d, cd16 e antígeno associado a tumor | |
| US20200165344A1 (en) | Proteins binding nkg2d, cd16 and flt3 | |
| BR112020015994A2 (pt) | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer | |
| BR112020003654A2 (pt) | proteínas de ligação ao nkg2d, cd16 e a um antígeno associado a tumor | |
| BR112020023299A2 (pt) | proteína de ligação nkg2d, cd16 e uma proteína de ativação de fibroblastos | |
| BR112019016553A2 (pt) | Proteínas que se ligam ao psma, nkg2d e cd16 | |
| US20200002436A1 (en) | Proteins binding cd123, nkg2d and cd16 | |
| BR112019017256A2 (pt) | proteínas de ligação gd2, nkg2d e cd16 | |
| BR112020016190B1 (pt) | Sítio de ligação ao antígeno que se liga a nkg2d, proteína, formulação compreendendo a mesma e seus usos | |
| BR112019016315A2 (pt) | Proteínas de ligação multiespecíficas para ativação de células natural killer e usos terapêuticos destas para tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |